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The tumor suppressive function of PTEN is exerted within 2 different cellular compartments. In the cytosol-
membrane, it negatively regulates PI3K-AKT pathway through the de-phosphorylation of phosphatidylinositol (3,4,5)-
triphosphate (PIP3), therefore blocking one of the major signaling transduction pathways in tumorigenesis. In the
nucleus, PTEN controls genomic stability and cellular proliferation through phosphatase independent mechanisms.
Importantly, impairments in PTEN cellular compartmentalization, changes in protein levels and post-transductional
modifications affect PTEN tumor suppressive functions. Targeting mechanisms that inactivate PTEN promotes apoptosis
induction of cancer cells, without affecting normal cells, with appealing therapeutic implications. Recently, we have
shown that BCR-ABL promotes PTEN nuclear exclusion by favoring HAUSP mediated PTEN de-ubiquitination in Chronic
Myeloid Leukemia. Here, we show that nuclear exclusion of PTEN is associated with PTEN inactivation in the cytoplasm
of CML cells. In particular, BCR-ABL promotes Casein Kinase II-mediated PTEN tail phosphorylation with consequent
inhibition of the phosphatase activity toward PIP3. Targeting Casein Kinase II promotes PTEN reactivation with
apoptosis induction. We therefore propose a novel BCR-ABL/CKII/PTEN pathway as a potential target to achieve
synthetic lethality with tyrosine kinase inhibitors.
Introduction
The tumor suppressor PTEN is one of the most frequently
mutated and deleted tumor suppressors in cancer.1,2 Its tumor
suppressive function is exerted within 2 different cellular com-
partments. In the cytosol-membrane, it negatively regulates
PI3K-AKT pathway through the de-phosphorylation of phos-
phatidylinositol (3,4,5)-triphosphate (PIP3), therefore blocking
one of the major signaling transduction pathways in tumorigene-
sis. In the nucleus, PTEN acts as a tumor suppressor by regulat-
ing genomic stability and cellular proliferation through
phosphatase independent mechanisms.1,3-5 Recently, PTEN has
been proposed as the paradigm for non genomic loss of function
of tumor suppressors.6,7 In particular, the tumor suppressive
functions of PTEN are tightly controlled by PTEN protein level,
cellular compartmentalization and post-trasductional modifica-
tions, such as phosphorylation, ubiquitination and sumoylation.1
Importantly, the identification of those cancers, where wild-type
PTEN is functionally inhibited, could have dramatic consequen-
ces from the therapeutic standpoint. The reactivation of the
tumor suppressor could indeed have tremendous and selective
consequences in cancer cells without affecting normal cells.
Chronic Myeloid Leukemia is a myeloproliferative disorder char-
acterized by the translocation t(9;22), coding for the chimeric
protein BCR-ABL.8-11 PTEN plays an essential role in the patho-
genesis of Chronic Myeloid Leukemia (CML).12,13 Recently we
have shown that BCR-ABL promotes PTEN nuclear exclusion
causing loss of PTEN tumor suppressive function in the
nucleus.13,14 The shuttling of nuclear PTEN into the cytoplasm
could imply that PTEN inhibits PI3K-AKT signaling in CML.
On the contrary, it is well demonstrated that BCR-ABL transfor-
mation requires PI3K-AKT signaling.15-25 Furthermore, it was
also shown that PIP3 levels are dramatically increased in CML.26
Therefore, we hypothesized that PTEN could be functionally
inactivated in the cytoplasm of CML cells. Here, we demonstrate
that BCR-ABL promotes the inactivation of cytoplasmic PTEN,
through the activity of the serine-threonine Casein Kinase II,
with potential therapeutic implications.
Results
To test whether cytoplasmic PTEN is able to regulate BCR-
ABL-induced PI3K-AKT signaling, we first assessed the phos-
phorylation status of AKT in CML progenitor cells. We recently
showed that Lin-CD34CCD38C CML progenitor cells and LinC
CML cells expressed PTEN mostly in the cytoplasm.13 Interest-
ingly, in Lin-CD34CCD38C CML progenitors cells AKT is
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mostly phosphorylated, suggesting that PI3K-AKT pathway is
active even in the presence of cytosolic PTEN (Fig. 1A;
Fig. S1A). Similarly, in BCR-ABL-NIH3T3 cells, where PTEN
is mostly cytosolic,13 AKT is phosphorylated, when detected by
Western immunoblot (Fig. 1B). As already shown by others,26
we also observed that PIP3 levels are substantially increased in
CML CD34 positive cells (Fig. 1C). Furthermore, PI3K-AKT
pathway was demonstrated to be necessary for BCR-ABL medi-
ated transformation.15 These data suggest that PTEN activity
could be impaired in CML. PTEN protein has been shown to be
under-expressed in CML patients.13,24,27 Expression of low levels
of PTEN could explain the inability of PTEN to promote PIP3
de-phosphorylation. However, the observation that not all CML
samples are characterized by markedly reduction of PTEN levels
prompted us to investigate other mechanisms of PTEN activity
regulation. In particular, PTEN activity is regulated by the
Casein Kinase II-mediated serine/threonine phosphorylation of
the tail.1 Therefore, we sought to assess PTEN tail phosphoryla-
tion in CML bone marrow samples. As shown in Figure 1D,
PTEN is highly phosphorylated. Interestingly, we observed high
levels of phosphorylation even in those samples where PTEN is
markedly under-expressed (Supplementary Fig. 1B). These
observations prompted us to investigate whether PTEN phospha-
tase is functionally inactivated through phosphorylation in CML.
We performed a PTEN phosphatase assay in CML cells, as
described in material and methods, and upon normalization of
the PTEN protein amounts (Fig. S1C). Interestingly, in primary
CML cells, PTEN activity is decreased when compared to nor-
mal bone marrow mononuclear cells (Fig. 1E). PTEN tail phos-
phorylation on serine/threonine residues by Casein Kinase II is
thought to cause a “tail-closed” conformation switch which pre-
vents PTEN from targeting its substrate at the membrane.28-30
Casein Kinase II is a serine/threonine kinase that is involved in
tumorigenesis.31 Notably, Casein Kinase II was described as a
druggable substrate of BCR-ABL, although its function in CML
is still unclear.32-35 Importantly, it was clearly demonstrated that
BCR-ABL/CKII complex plays an essential role in the regulation
of imatinib resistance.36 To verify whether PTEN tail phosphor-
ylation is regulated by BCR-ABL, the BCR-ABL inhibitor imati-
nib and/or the casein kinase inhibitor TBB were utilized in
BCR-ABL expressing NIH3T3 cells and PTEN phosphorylation
levels were assessed by western immunoblot, upon normalization
of PTEN levels. As shown in Figure 2A, the association Imatinib
and TBB revert PTEN tail phosphorylation induced by BCR-
ABL. Although with less extend, similar conclusions were
observed in the 32D-BCR-ABL cell lines, as reported in Figure
S1D. These observations suggest that BCR-ABL promotes
PTEN phosphorylation through Casein Kinase II, that was
reported to occur at specific serine/threonine residues located in
the tail (Fig. 2B). To better address the role of Casein Kinase II
in the phosphorylation of PTEN, we first confirmed that BCR-
ABL physically interacts with CKII, as previously reported
(Fig. 2C).32,34,36 Next, to determine whether BCR-ABL medi-
ates PTEN phosphorylation by Casein Kinase II, we performed
an in vitro kinase assay with purified ABL protein and with
PTEN and CKII immunoprecipitated proteins, as described in
Material and Methods. As shown in Figure 2D, the presence of
ABL increases PTEN phosphorylation induced by CKII. Treat-
ment with imatinib reverts ABL effects on CKII, suggesting that
ABL can increase CKII activity toward PTEN. Next, to assess
whether PTEN-tail phoshorylation by BCR-ABL/CKII causes
PTEN inactivation, we generated PTEN-tail mutants (S370A,
TM: S380A/T382A/T383A, S385A) in Myc-tag-pRK5 and
pGFP-C2-PTEN vectors. We expressed these vectors in
NIH3T3 cells due to the wide cytoplasm/nuclear ratio that
allows to better evaluate cellular compartmentalization. These
PTEN mutants were already shown to be unstable, able to reach
the membrane in un-stimulated conditions and associated with
increased PTEN phosphatase activity.37 Expression of myc-
tagged-PTEN tail-mutants in BCR-ABL NIH3T3 cells enabled
PTEN to reach the membrane (Fig. 2E). Due to the instability
of PTEN-S385A and PTEN-S370A, we decided to focus on the
more stable PTEN-TM mutant. To test PTEN activity in the
presence of BCR-ABL, BCR-ABL-NIH3T3 cells were
transfected with GFP-tagged-PTEN-WT and GFP-tagged-
PTEN-TM. Interestingly, when we measured GFP-tagged
PTEN activity in BCR-ABL-NIH3T3 cells, we observed that
PTEN-WT is less active than in parental cells, while expression
of PTEN-TM substantially increases PTEN activity, even in the
BCR-ABL context (Fig. 3A; Fig. S2A). In line with these consid-
erations, expression of PTEN-TM was associated with increased
apoptosis induction (Fig. 3B). Importantly, PTEN-tail de-phos-
phorylation is therapeutically achievable by treatment with CKII
inhibitors. Treatment of BCR-ABL NIH3T3 cells with CKII
inhibitor TBB was indeed associated with apoptosis induction
(Fig. 3C; Fig. S2B). The utility of Casein Kinase inhibitors has
already been tested in CLL and in other hematological disor-
ders.36,38-43 A major therapeutic challenge in the treatment of
CML is the therapy of BCR-ABL-T315I and other BCR-ABL
mutations that are responsible of mediating tyrosine kinase
inhibitors (TKIs) resistance. To test whether CKII promotes apo-
ptosis in imatinib resistant CML, we treated a T315I-BCR-ABL
CML bone marrow sample with 60 mM TBB for 10 hours con-
firming that TBB promotes apoptosis induction in Imatinib-
resistant primary cells (Fig. 4A).
Discussion
In this work, we have demonstrated that BCR-ABL is able to
induce non-genomic loss of function of PTEN by favoring CKII
mediated tail phosphorylation, which in turn inhibits PTEN
activity (Fig. 4B). Furthermore, we provided evidences that CKII
inhibition could promote PTEN reactivation with therapeutic
implications especially in those situations of resistance to imati-
nib, due to BCR-ABL point mutations. The existence of a BCR-
ABL/CKII complex has already been solidly demonstr-
ated.32-34,36 Moreover, targeting CKII has been described as a
powerful therapeutic option in BCR-ABL leukemias.33,36 How-
ever, BCR-ABL/CKII mechanisms of activation and targets are
still an issue of debate. Previous reports have clearly demon-
strated that BCR-ABL promotes CKII activation.32,36 Only one
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Figure 1. Cytoplasmic PTEN is functionally inhibited by BCR-ABL. (A) Representative Phosho-AKT immunofluorescence staining in primary CML
Lin-CD34CCD38C and LinC cells. PI: propidium iodide; P-AKT: phospho-Ser473-AKT. (B) Western immunoblot on Phospho-Ser473-AKT and Phospho-ERK
in BCR-ABL-NIH3T3 cells. (C) Representative phosphatidylinositol (3,4,5)-triphosphate (PIP3) staining immunofluorescence in CD34 normal bone marrow
and CML sample; PIP3 immunofluorescence staining intensity quantification with ImageJ software in 25 cells per conditions. (D) Upper panel: western
immunoblot of primary total bone marrow CML extracts. Phospho-PTEN: Phospho-S380/T382/T383. Lower panel: quantification of Phospho-PTEN/PTEN
in CML cases #1,#2,#3 of the western presented in the upper panel and CML cases #4,#5,#6 shown in the Supplementary Figure 1 B compared to the 2
normal bone marrow cases; *P <0.05. (E) Evaluation of PTEN activity in CML cases #1,#2,#3 of panel (d) and 2 normal bone marrow samples. A.U.: arbi-
trary unity; *P<0.05.
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report described that BCR-ABL inhibits CKII.34 The mechanism
of CKII activation by BCR-ABL appeared to be highly complex.
CKII is indeed referred as a constitutively active kinase, whose
regulation depends on protein
levels or interactions. However,
some tyrosine kinases have also
been reported to promote its
activation though direct phos-
phorylation.44 Previous works
did confirmed that BCR-ABL
induces tyrosine phosphorylation
of CKII-a, but this event did not
appear to increase its catalytic
activity.31,35 Our data are in line
with these evidences, although
more insights are necessary to
investigate how CKII is activated
by BCR-ABL. An additional
layer of complexity to study
BCR-ABL/CKII/PTEN complex
in CML is represented by the
heterogeneity of CML cells,
ranging from the rare leukemia
stem cells, to progenitors and dif-
ferentiate elements. Mechanisms
of regulation of the BCR-ABL/
CKII/PTEN complex could
indeed be differentially affected
by protein levels and interac-
tions. Therefore, data regarding
BCR-ABL/CKII/PTEN in CML
could be affected by the type of
samples collected (cell lines ver-
sus sorted cells vs. total bone
marrow), rendering these studies
really challenging. The novelty
of our investigation relies on the
identification of the target of the
BCR-ABL/CKII complex, which
is PTEN. We have demonstrated
that BCR-ABL/CKII promotes
PTEN phosphorylation with
impairment of its phosphatase
activity. Although PTEN activity
could be affected by different
mechanisms, in particular pro-
tein under-expression/delocaliza-
tion, it is clear that PTEN
inactivation by BCR-ABL/CKII
represents a targetable opportu-
nity. The identification of this
mechanism could have profound
implications from the therapeu-
tic standpoint. The reactivation
of PTEN tumor suppressive
function in the context of an
oncogene addicted cell represents a powerful pro-apoptotic stim-
ulation with potentially few effects on the normal cells.45 Similar
observations have been obtained in other hematological cancers,
Figure 2. BCR-ABL promotes PTEN inactivation through Casein Kinase II. (A) PTEN-phosphorylation in parental
and BCR-ABL-NIH3T3 treated with 1 mM imatinib and 60 mM TBB for 10 hours. To obtain a comparable level
of expression of PTEN, the amount of BCR-ABL-NIH3T3 extracts were increased of 20% compared to parental
NIH3T3 cells. (B) Schematic representation of PTEN with the indication of PTEN tail phosphorylation sites. (C)
Co-immunoprecipitation of CKII-a and p210-BCR-ABL in BCR-ABL-infected NIH3T3 cells. (D) In vitro kinase
assay with immunoprecipitated PTEN and CKII-a and purified ABL kinase. One mM Imatinib was added to the
in vitro reaction for 10 minutes. Phospho-PTEN: Phospho-S380/T382/T383; P-Tyr: Phospho-Tyrosine: the band
corresponds to the BCR-ABL molecular weight. (E) Transient transfection of Myc-PTEN mutants in BCR-ABL-
infected NIH3T3 cells. 48 hours after transfection, myc-tag immunofluorescence was performed to verify PTEN
compartmentalization. PTEN-TM: PTEN-S380A/T382A/T383A.
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where CKII inhibitors have been
associated with dramatic apoptosis
induction.36,38–41 From a clinical
perspective regarding CML ther-
apy, we suggest that CKII inhibi-
tors could be exploited to target
imatinib resistant CML, due to
BCR-ABL point mutations, and
in particular by BCR-ABL-T315I.
In these circumstances, CKII
inhibitors promote PTEN reacti-
vation in the presence of a sus-
tained BCR-ABL signaling with a
consequent apoptosis induction.
Materials and Methods
Cells and reagents
The following antibodies were
used: ABL (#131; Santa Cruz Bio-
technology), Phospho-ERK
(#9101; Cell Signaling), Phospho-
AKT S473 (#3787; Cell
Signaling), Tubilin (#2146; Cell
Signaling), phospho-PTEN-S385
(#54434; Ana Spec), phospho-
PTEN-Ser370 (#11062; Signal-
way antibody), phospho-PTEN-
Ser380/Thr382/383 (#9549; Cell
Signaling), PTEN (#9552; Cell
Signaling), PtdIns(3,4,5)P3
(#A21328; Molecular Probes),
Casein Kinase II-a (#12738; Santa
Cruz Biotechnologies), Phospho-
Tyrosine (#7020; Santa Cruz
Biotechnologies). Secondary anti-
bodies were: goat anti-mouse IgG-
HRP (Santa Cruz, # 2005) and
goat anti-rabbit IgG-HRP (Santa
Cruz, #2004). 32D cells line and
Wehi-3B cells were purchased
from DSMZ vendor. NIH3T3
cells were from ATCC. Parental
32D cells were growth in the pres-
ence of 10%Wehi-3B conditioned
medium. TBB was purchased from Sigma-Aldrich. TBB and
imatinib were used at a concentration of 60 mM and 1 mM,
respectively, for 10 hours, unless specifically indicated.
Plasmid, mutagenesis and transfection
pBABE-BCR-ABL, pRK5-myc-tag-PTEN and pEGFP-C2-
PTEN expressing vectors have been described elsewhere.13
PTEN mutants were generated using the Quick-change II-XL
(Stratagene, #200523) site directed mutagenesis kit. Transfection
was performed using Lipofectamine 2000 (Invitrogen) or
X-treme GeneHP (Roche). NIH3T3 infections with pBABE-
BCR-ABL vector and empty-pBABE vector were performed as
previously reported.13 BCR-ABL-32D cell lines were generated
by electroporation of pBABE-BCR-ABL followed by puromycin
selection.
Western immunoblot, immunoprecipitation
and Immunofluorescence
Western immunoblot and immunofluorescence was per-
formed as previously described.13 Each western immunoblot and
immunoprecipitation experiments were repeated at least 2 times.
Figure 3. PTEN reactivation promotes apoptosis in BCR-ABL positive cells. (A) Parental and BCR-ABL-NIH3T3
were transfected with the indicated GFP-tagged-PTEN vectors. After 48 hours, PTEN phosphatase assay was
performed in immunoprecipitated GFP-PTEN. *P <0.05; **P<0.01. (B) Western immunoblot of BCR-ABL-
NIH3T3 cells transfected with the indicated GFP-PTEN mutants. Phospho-PTEN: PTEN-S380/T382/T383. (C)
Apoptosis was assessed in NIH3T3 cells treated with 60 mM TBB and 1 mM Imatinib for 10 hours. Data are
mean and d.s. of two independent experiments. After short incubation period with inhibitors, in BCR-ABL-
NIH3T3 cells, solvent vs. TBB and solvent vs. TBB/imatinib differences are significant with *P<0.05.
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PIP3 immunofluorescence intensity staining was measured with
ImageJ software.
PTEN activity assay.
PTEN activity was measured accordingly to manufacturer’s
protocol (Echelon, #K4700). In particular, equal amounts of
PTEN proteins were immunoprecipitated as the source for the
enzyme reaction. Standard curve and dose response (variable
slope) correlation was analyzed using GraphPad software.
Human CML samples and ethics statement
Primary CML bone marrow samples were collected with
informed consent at the time of diagnosis from untreated
patients. CD34 positive cells were isolated from bone marrow
aspirate accordingly to the Miltenyi Biotec protocol for CD34
purification (Miltenyi Biotec, #130–094–531). This project was
reviewed and approved by the San Luigi Hospital Institutional
Ethical Committee (Code # 10/2013).
Flow cytometry
Sorting of Lin-CD34CCD38C cells were performed as previ-
ously described.13,46 Apoptosis quantification was performed
with PE-annexin V/7-AAD (BD Biosciences).
Kinase assay
PTEN Kinase assay has been performed as previously
described.13 In particular, PTEN and CKII were immunopreci-
pitated from untreated cells and incubate with purified full-
length ABL protein (Invitrogene, #P3049) and 10 mM ATP.
When indicated, 1 mM imatinib was added to the in vitro reac-
tion for 10 minutes.
Statistical analyses
Two-side Student’s t test and one-way ANOVA were calcu-
lated using GraphPad Prism software. P values < 0,05 were con-
sidered statistically significant. Data represent the average § SE.
*P<0.05; **P<0.01.
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